Molecular Studies of Cutaneous Lupus
We aim to identify novel pathogenic proteins and genetic profiles in three different subtypes of cutaneous lupus patients and compare them to age-, sex-, and gender-matched SLE without CLE, immune-mediated skin disease (i.e. psoriasis) control, and normal control patients. All patients will be classified into ACLE, SCLE, and DLE, and immune-mediated skin diseases according to their clinical, histopathological, and laboratory findings. Since this is a tissue repository, an indefinite number of cutaneous lupus, SLE with CLE, immune-mediated skin disease (i.e. psoriasis and eczema), and normal control subjects will be enrolled during an indefinite period of time.
From each group of cutaneous lupus and immune-mediated skin disease control patients, each patient will submit blood samples and undergo skin biopsies for further analysis. Each SLE without CLE patient will provide a blood sample, and each normal control patient will submit a skin sample from cutaneous and plastic surgeries, and/or a blood sample. All blood and skin samples will undergo protein expression studies including extensive array-based screens, immunohistochemistry, and flow cytometry, while DNA will be extracted from blood samples for genetic profiling studies including SNP analysis. In addition, patient demographic information, lupus history, past medical history, family history, medication, quality of life information, laboratory data, clinical assessment, dietary habits, and sun-protective habits will be obtained.
The criteria for inclusion of the CLE patient study group include a diagnosis with cutaneous lupus erythematosus by clinical, histopathological, and laboratory findings, age 18 years and older, male or female gender, any ethnic background, ability to speak and read English or Spanish at a 6th grade reading level, and ability to give written informed consent. The criteria for inclusion of the SLE without CLE patient study group are similar as the CLE patient study group except for the requirements of at least four American College of Rheumatology criteria established for SLE diagnosis and absent history of cutaneous lupus. The criteria for inclusion of the immune-mediated skin disease control group (i.e. psoriasis) are similar as the CLE patient study group except that histopathological tests are not required if clinical with or without laboratory findings are sufficient for diagnosis.
The criteria for inclusion of the control study group include negative history of autoimmune diseases, age 18 years and older, male or female gender, any ethnicity, ability to speak and read English or Spanish at a 6th grade reading level, ability to give written informed consent, and surgical procedure resulting in creation of surgical waste by no other action than the surgery itself. This group may include first degree relatives of patients diagnosed with cutaneous lupus.